Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Nanobiotix ( (NBTX) ).
On December 17, 2025, Nanobiotix released details regarding its share capital and voting rights as of November 30, 2025. The company reported 48,401,118 outstanding shares with 50,079,581 exercisable voting rights. This update underscores its commitment to transparency for stakeholders and compliance with regulatory standards, potentially bolstering investor confidence and affirming the company’s competitive positioning in the biotechnology industry.
The most recent analyst rating on (NBTX) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
Nanobiotix’s overall stock score is primarily impacted by its poor financial performance, with significant operational losses and financial instability. While technical analysis shows some positive momentum, the negative valuation metrics due to lack of profitability further weigh down the score.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a Paris-based biotechnology company established in 2003, specializing in groundbreaking, physics-based therapeutic innovations targeting better health outcomes. The company focuses on applications in oncology, bioavailability, biodistribution, and central nervous system disorders, and it holds over 25 patent families. Listed on Euronext Paris since 2012 and Nasdaq since 2020, Nanobiotix also has subsidiaries in Cambridge, Massachusetts, among other locations.
Average Trading Volume: 96,372
Technical Sentiment Signal: Buy
Current Market Cap: $1.07B
For an in-depth examination of NBTX stock, go to TipRanks’ Overview page.